PreveCeutical Medical logo

PreveCeutical Medical(OTC) PRVCF

Market Cap$6.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-92%
5 Year-58%
1 Year-64%
1 Month-58%
$0.01
-19.15%
-0.00Today
PreveCeutical Medical last closing stock price
MetricPriceDate
Last closeUSD 0.012026-10-13
PreveCeutical Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-37.65%USD 0.012026-10-06
1 month-57.54%USD 0.022026-09-11
3 month-25.49%USD 0.012026-07-10
Year to date-57.06%USD 0.022025-12-31
1 year-64.07%USD 0.022025-10-13
3 year-58.47%USD 0.022023-10-13
5 year-58.01%USD 0.022021-10-14
Since inception-92.09%USD 0.122017-08-21

PreveCeutical Medical Financials at a Glance

Market Cap

$6.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$689.26K

EPS (TTM)

-$0.00

P/E Ratio

-4.48

Dividend

$0.00

Beta (Volatility)

-0.05 (Low)

Price

$0.01

Volume

6,878

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.00 - $0.04

Estimated Earnings Date

Apr 30, 2026

PRVCF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PreveCeutical Medical

PreveCeutical Medical Inc. is a Vancouver-based health sciences company focused on developing innovative preventative and curative treatments derived from organic and nature-identical substances. The company’s pipeline includes a cannabinoid Sol-Gel Delivery system and various medicinal products aimed at addressing significant health challenges.

Products and Services
  • Cannabinoid Sol-Gel Delivery system for nose-to-brain administration
  • BSV Peptide Program targeting cancer progression
  • Non-addictive analgesic for effective pain management
Growth Outlook
  • Innovative product pipeline positions the company for future market opportunities
  • Focus on cannabinoid-based therapies aligns with growing health trends
  • Potential partnerships could enhance research and development capabilities
Financial Highlights
  • Recent quarterly net income of -$541,332 reflects ongoing investment in R&D
  • Trailing twelve months show a negative P/E ratio of -16.67, indicating potential for future growth
  • Market capitalization of approximately $7.82 million suggests room for expansion
PreveCeutical Medical Inc. operates in the biotechnology sector, emphasizing the development of health solutions that leverage the therapeutic potential of cannabinoids and peptides. The company is actively engaged in research and development, with a focus on creating non-addictive pain management solutions and therapies for serious conditions such as cancer and diabetes. The growth outlook for PreveCeutical is promising, driven by an innovative product pipeline and alignment with current health trends favoring natural and preventative treatments. The company’s financial position, while currently showing losses, reflects significant investment in research and development, which could lead to future profitability as products move closer to market readiness. Investors may find interest in the company's strategic initiatives and the potential for partnerships that could enhance its capabilities and market reach. The biotechnology sector continues to attract attention, and PreveCeutical's focus on cannabinoid-based therapies positions it well within this evolving landscape.
AI Generated • Sep 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Stephen van Deventer

Website

www.preveceutical.com

Headquarters

Vancouver, BC V7W 2R2, CA

PRVCF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

10.15%

Return on Capital

N/A

Return on Assets

-45.47%

Earnings Yield

-22.32%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

638.19M

Volume

6.88K

Avg. Volume

21.80K

Financials (TTM)

Gross Profit

-CA$7.25K

Operating Income

-CA$2.30M

EBITDA

-CA$2.26M

Operating Cash Flow

-CA$1.60M

Capital Expenditure

-CA$5.58

Free Cash Flow

-CA$1.60M

Cash & ST Invst.

CA$35.66K

Total Debt

CA$4.84M

PreveCeutical Medical Performance Analysis

PreveCeutical Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 0N/A
20232023-12-31CAD 0N/A
20242024-12-31CAD 0N/A
20252025-12-31CAD 0N/A
PreveCeutical Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
PreveCeutical Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.00-18.5%
20232023-12-31CAD -0.00-18.2%
20242024-12-31CAD -0.00-11.1%
20252025-12-31CAD -0.0025.0%
PreveCeutical Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3036.4%
Q42025-12-31250.0%
Q12026-03-31-142.9%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

CA$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$6.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$857.00K

N/A

Employees

7

N/A

Net Income

-CA$541.33K

+56.9%

EBITDA

-CA$384.20K

+67.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$35.66K

+737.1%

Total Debt

CA$4.84M

+6.4%

Accounts Receivable

CA$0.00

-100.0%

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

-100.0%

Short Term Debt

CA$4.84M

+7.9%

Return on Assets

-45.47%

N/A

Return on Invested Capital

37.59%

N/A

Free Cash Flow

-CA$273.46K

+51.4%

Operating Cash Flow

-CA$273.46K

+51.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AVCN.TOAvicanna Inc.
CA$0.12+9.52%
LABS.TOMediPharm Labs Corp.
CA$0.07-7.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About PRVCF

What is the current price of PreveCeutical Medical?

PreveCeutical Medical is trading at $0.01 per share.

What is the 52-week range for PreveCeutical Medical?

Over the past 52 weeks, PreveCeutical Medical has traded between $0.00 and $0.04.

How much debt does PreveCeutical Medical have?

As of the most recent reporting period, PreveCeutical Medical reported total debt of CA$3.41M.

How much cash does PreveCeutical Medical have on hand?

PreveCeutical Medical reported CA$7.47K in cash and cash equivalents in its most recent financial results.

What is PreveCeutical Medical’s dividend yield?

PreveCeutical Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services